NCT02766647View on ClinicalTrials.gov

A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

March 31, 2016

Conditions
Neutropenia (Low White Blood Cell Count)
Interventions
BIOLOGICAL

Filgrastim Hospira (US)

5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection

BIOLOGICAL

US-approved Neupogen®

5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection

Trial Locations (1)

33126

SeaView Research, Inc, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Pfizer

INDUSTRY

NCT02766647 - A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen) | Biotech Hunter | Biotech Hunter